Janice L. Holton

Janice L. Holton

Auto-generated profile, based on publicly available information

Janice L. Holton

Queen Square Brain Bank for Neurological Disorders UCL Queen Square Institute of Neurology London UK

Research Focus & Metrics

Academic Career Length

26Years (2001-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
27 July 2020 in Neuropathology and Applied Neurobiology
Verified
Journal Article
Open access
PDF file
DHDaniela Hansen
Daniela Hansen
HLHelen Ling
Helen Ling
TLTammaryn Lashley
Tammaryn Lashley
JFJennifer A. Foley
Jennifer A. Foley
CSCatherine Strand
Catherine Strand
TWThomas T. Warner
Thomas T. Warner
Dementia with Lewy bodies (DLB) and Parkinson’s disease dementia (PDD) known as Lewy body dementias have overlapping clinical and neuropathological features. Neuropathology in both includes combination of Lewy body and Alzheimer’s disease (AD) pathology. Cerebral amyloid angiopathy (CAA), often seen in AD, is increasingly recognized for its association with dementia.Aims: This study investigated clinical and neuropathological differences between DLB and PDD.Methods: 52 PDD and 16 DLB cases from the Queen Square Brain Bank (QSBB) for Neurological disorders were included. Comprehensive clinical data of motor and cognitive features were obtained from medical records. Neuropathological assessment included examination of CAA, Lewy body and AD pathology.Results: CAA was more common in DLB than in PDD (P = 0.003). The severity of CAA was greater in DLB than in PDD (P = 0.009), with significantly higher CAA scores in the parietal lobe (P = 0.043), and the occipital lobe (P = 0.008), in DLB than in PDD. The highest CAA scores were observed in cases with APOE ε4/4 and ε2/4. Survival analysis showed worse prognosis in DLB, as DLB reached each clinical milestone sooner than PDD. Absence of dyskinesia in DLB is linked to the significantly lower lifetime cumulative dose of levodopa in comparison with PDD.Conclusions: This is the first study which identified prominent concurrent CAA pathology as a pathological substrate of DLB. More prominent CAA and rapid disease progression as measured by clinical milestones distinguish DLB from PDD.

3 June 2019 in Cold Spring Harbor Molecular Case Studies
Verified
Journal Article
Open access
PDF file
RLRuth Lamb
Ruth Lamb
JRJonathan D. Rohrer
Jonathan D. Rohrer
RRRaquel Real
Raquel Real
SLSteven J. Lubbe
Steven J. Lubbe
AWAdrian J. Waite
Adrian J. Waite
HMHuw R. Morris
Huw R. Morris
Mutations in the TANK-binding kinase 1 (TBK1) gene have recently been shown to cause frontotemporal dementia (FTD) and amyotrophic lateral sclerosis (ALS). The phenotype is highly variable and has been associated with behavioral variant FTD, primary progressive aphasia, and pure ALS. We describe the clinical, anatomical, and pathological features of a patient who developed corticobasal syndrome (CBS)/progressive nonfluent aphasia (PNFA) overlap. The patient presented with progressive speech difficulties and later developed an asymmetric akinetic–rigid syndrome. Neuroimaging showed asymmetrical frontal atrophy, predominantly affecting the right side. There was a strong family history of neurodegenerative disease with four out of seven siblings developing either dementia or ALS in their 50s and 60s. The patient died at the age of 71 and the brain was donated for postmortem analysis. Histopathological examination showed frontotemporal lobar degeneration TDP-43 type A pathology. Genetic screening did not reveal a mutation in the GRN, MAPT, or C9orf72 genes, but exome sequencing revealed a novel p.E703X mutation in the TBK1 gene. Although segregation data were not available, this loss-of-function mutation is highly likely to be pathogenic because it is predicted to disrupt TBK1/optineurin interaction and impair cellular autophagy. In conclusion, we show that TBK1 mutations can be a cause of an atypical parkinsonian syndrome and screening should be considered in CBS patients with a family history of dementia or ALS.

6 June 2011 in Muscle & Nerve
Verified
Journal Article
Closed access
PDF file
SRSanjeev Rajakulendran
Sanjeev Rajakulendran
MPMatt Parton
Matt Parton
JHJanice L. Holton
Janice L. Holton
MHMichael G. Hanna
Michael G. Hanna

1 January 2001 in Amyloid
Verified
Journal Article
Closed access
PDF file
JGJorge Ghiso
Jorge Ghiso
TRTamas Révész
Tamas Révész
JHJanice Holton
Janice Holton
ARAgueda Rostagno
Agueda Rostagno
TLTammaryn Lashley
Tammaryn Lashley
BFBias Frangione
Bias Frangione
Two hereditary conditions, familial British dementia (FBD) and familial Danish dementia (FDD), are associated with amyloid deposition in the central nervous system and neurodegeneration. The two amyloid proteins, ABri and ADan, are degradation products of the same precursor molecule BriPP bearing different genetic defects, namely a Stop-to-Arg mutation in FBD and a ten-nucleotide duplication-insertion immediately before the stop codon in FDD. Both de novo created amyloid peptides have the same length (34 amino acids) and the same post-translational modification (pyroglutamate) at their N-terminus. Neurofibrillary tangles containing the classical paired helical filaments as well as neuritic components in many instances co-localize with the amyloid deposits. In both disorders, the pattern of hyperphosphorylatedtau immunoreactivity is almost indistinguishable from that seen in Alzheimer's disease. These issues argue for the primary importance of the amyloid deposits in the mechanism(s) of neuronal cell loss. We propose FBD and FDD, the chromosome 13 dementia syndromes, as models to study the molecular basis of neurofibrillary degeneration, cell death and amyloid formation in the brain.

1 July 2005 in Archives of Neurology
Verified
Journal Article
Open access
PDF file
AGAlison Godbolt
Alison Godbolt
KJKeith A. Josephs
Keith A. Josephs
TRTamas Revesz
Tamas Revesz
EWElizabeth K. Warrington
Elizabeth K. Warrington
PLPeter Lantos
Peter Lantos
MRMartin N. Rossor
Martin N. Rossor
The pathology underlying frontotemporal lobar degeneration (FTLD) has been defined more clearly in recent years.1 Clinical and pathological features overlap, such that apparently similar clinical presentations can be due to different histopathological abnormalities. Frontotemporal lobar degeneration also occurs in both familial and sporadic forms, with 10% to 50% of cases being familial.2 It is not clear whether sporadic disease and familial disease differ in clinical phenotype. Mutations in the tau gene occur in only half of familial cases.3 At least 3 different gene loci have been proposed for familial FTLD occurring without tau deposition or tau mutations.4 An understanding of the similarities or otherwise of familial and sporadic disease will become increasingly important when these genes are identified.

23 December 2020 in Neuropathology and Applied Neurobiology
Verified
Journal Article
Open access
PDF file
CBConceição Bettencourt
Conceição Bettencourt
YMYasuo Miki
Yasuo Miki
Ignazio PirasIgnazio Piras
Ignazio Piras
RSRohan de Silva
Rohan de Silva
SFSandrine C. Foti
Sandrine C. Foti
JHJanice L. Holton
Janice L. Holton
Aims: Multiple system atrophy (MSA) is a fatal neurodegenerative disease. Similar to Parkinson's disease (PD), MSA is an α‐synucleinopathy, and its pathological hallmark consists of glial cytoplasmic inclusions (GCIs) containing α‐synuclein (SNCA) in oligodendrocytes. We previously identified consistent changes in myelin‐associated oligodendrocyte basic protein (MOBP) and huntingtin interacting protein 1 (HIP1) DNA methylation status in MSA. We hypothesized that if differential DNA methylation at these loci is mechanistically relevant for MSA, it should have downstream consequences on gene regulation.Methods: We investigated the relationship between MOBP and HIP1 DNA methylation and mRNA levels in cerebellar white matter from MSA and healthy controls. Additionally, we analysed protein expression using western blotting, immunohistochemistry and proximity ligation assays.Results: We found decreased MOBP mRNA levels significantly correlated with increased DNA methylation in MSA. For HIP1, we found a distinct relationship between DNA methylation and gene expression levels in MSA compared to healthy controls, suggesting this locus may be subjected to epigenetic remodelling in MSA. Although soluble protein levels for MOBP and HIP1 in cerebellar white matter were not significantly different between MSA cases and controls, we found striking differences between MSA and other neurodegenerative diseases, including PD and Huntington's disease. We also found that MOBP and HIP1 are mislocalized into the GCIs in MSA, where they appear to interact with SNCA.Conclusions: This study supports a role for DNA methylation in downregulation of MOBP mRNA in MSA. Most importantly, the identification of MOBP and HIP1 as new constituents of GCIs emphasizes the relevance of these two loci to the pathogenesis of MSA.